Connecting...

W1siziisimnvbxbpbgvkx3rozw1lx2fzc2v0cy9uzxh0lxboyxnllxjly3j1axrtzw50l2pwzy9iyw5uzxitzgvmyxvsdc5qcgcixv0

Head of Intellectual Property - Cell & Gene Therapies

Head of Intellectual Property - Cell & Gene Therapies

Job Title: Head of Intellectual Property - Cell & Gene Therapies
Contract Type: Permanent
Location: London
Industry:
Salary: £70000 - £78000 per annum, Benefits: Bonus, pension and other excellent benefits
Start Date: 2019-07-31
Reference: 16314JH
Contact Name: James Hume
Contact Email: james.hume@nextphaserecruitment.com
Job Published: August 01, 2019 15:40

Job Description

A Biotech at the fore front of the commercialisation of Cell & Gene Therapies are recruiting for a Head of Intellectual Property Manager.  Who will become a key part of the senior team by developing and driving strategies for the management and realisation of IP.  The company are a centre of excellence that is leading the way in the development of cell & gene therapies by providing the multi - disciplinary expertise needed to bring these to the market.  Taking cutting edge therapies across the translational gap, into the clinic through trials to launch.
 
Role Summary:
 
The Head of Intellectual Property will develop and lead the IP strategy of the company covering their core funded, collaborative R&D and internal research activities.  You will be the expert in this field with the responsibility for providing advice to the senior management on the corporate strategic direction as well as to project teams.  Taking information form large volumes of biological data from diverse sources to develop recommendations.
 
The Head of IP will be responsible for the management and oversight of the company’s IP from identification, through drafting patent applications, to managing applications through the process to final grant and ongoing portfolio management. You will play a key role in developing the IP licensing terms for a broad range of contracts including service agreements, in license, out license, and collaborative R&D projects. Plus, the protection of core funded projects and accordingly undertake IP due diligence such as infringement analysis, validity of granted patents via patent prosecution analysis to make 3rd party observations or enter opposition proceedings.  They use external Patent Attorney’s whom you will communicate with to prepare applications, seek advice regarding specific issues.
 
To complement the internal focus, you will be responsible for working with collaborators to ensure they adopt IP best practice to support their growth and of the industry – a core part of their mission as a company.
  
Desired Skills and Competencies:
 
For this role, you will need to have demonstrable experience of Intellectual Property management within the life science / pharmaceutical / biotech sectors or technology transfer environment.  With the commercial ability to provide strategic advice based on biological data available to determine strategies.  As well as experience of managing IP Portfolios to ensure its potential is realised and its protection.  If you are a qualified patent attorney this is advantageous to your application but is not essential.  You will need experience of drafting patents either with or without external attorney assistance.    With the ability to identify and capture new patentable inventions internally and during collaborations.
  
The Company:
 
The company are a centre of excellence that is at the forefront of creating a viable and sustainable cell and gene therapy industry in the UK.  Their headquarters are in central London where they have built a market leading multidisciplinary team that has the ability to take a therapy from concept through the development cycle to the market.  They collaborate with both academia and industry and they are able to provide the scientific, clinical and commercial expertise needed to overcome the challenges that hinder the commercialisation of these fast developing, cutting edge technologies.  Their longer term aim is to make the UK a global leader in the development and commercial exploitation of therapies.  They are making great strides towards this aim with therapies entering phase 2 clinical trials and building credible cases to be progressed to stage 3.  Added to this they are expanding their manufacturing and development operations to meet increased demand for their services from the academic and commercial sectors.